IPG PHOTONICS ANNOUNCES THIRD QUARTER 2026 FINANCIAL RESULTS
Double-Digit Revenue Growth Driven by Strategic Initiatives Across Industrial and Advanced Solutions
November 3, 2026 - IPG Photonics Corporation (NASDAQ: IPGP) today reported financial results for the third quarter ended September 30, 2026.
*Adjusted gross margin, adjusted EBITDA and adjusted earnings per diluted share include non-GAAP adjustments. A reconciliation from GAAP to non-GAAP metrics is provided in this earnings release.
“We delivered our fourth consecutive quarter of double-digit year-over-year revenue growth, with revenue above the midpoint of our guidance,” said Dr. Mark Gitin, Chief Executive Officer of IPG Photonics. “Our performance reflects the strength of our technology, disciplined execution, and continued progress in expanding our presence in attractive, higher-growth markets. Strong demand for our differentiated welding and additive manufacturing solutions drove growth in Industrial Solutions while disciplined execution of our key strategic initiatives across defense and semiconductor markets led to strong growth in Advanced Solutions. Additionally, I anticipate that our acquisition of Lumibird Medical, which is expected to close in the fourth quarter, will further strengthen our reach, accelerate growth across medical markets, and increase revenue in Advanced Solutions.”
Third quarter revenue of $288 million increased 15% year over year, driven by 12% growth in Industrial Solutions and 33% growth in Advanced Solutions. Changes in foreign exchange rates increased revenue by approximately 1%. Industrial Solutions sales, accounting for 83% of total revenue, were driven by strong performance in welding and additive manufacturing applications. Advanced Solutions sales improved, driven by higher sales in semico nductor and defense applications. Emerging growth products accounted for 52% of total revenue, down from 58% in the prior quarter due to product mix. By region, sales increased 14% in Asia and 33% in North America and decreased 1% in Europe on a year-over-year basis.
GAAP gross margin of 40.7% and adjusted gross margin of 41.0% increased year over year, driven by lower product costs and $5.0 million in net tariff refunds recorded in the period, partially offset by lower fixed cost absorption. Net income was $20 million, or $0.47 per diluted share, and a djusted EBITDA was $52 million and adjusted earnings per diluted share (EPS) was $0.61 in the third quarter. During the third quarter, IPG generated $46 million in cash flow from operations and spent $17 million on capital expenditures.
“Our third quarter book-to-bill was approximately one as we continued to see improved industrial demand and executed on our strategic growth initiatives, driving adoption for our differentiated laser and photonics solutions that deliver measurable value to customers. As we move forward, we remain focused on driving profitable growth through innovation, technology differentiation, and operational excellence across our portfolio, ” concluded Dr. Gitin.
For the fourth quarter of 2026, IPG expects revenue of $265 million to $295 million, adjusted gross margin between 37.0% and 40.0% and adjusted operating expenses of $91 million to $94 million. IPG anticipates delivering adjusted earnings per diluted share in the range of $0.30 to $0.60 and adjusted EBITDA in the range of $33 million to $50 million. The guidance assumes no contribution from the acquisition of Lumibird Medical.
As discussed in more detail in the "Safe Harbor" passage of this news release, actual results may differ from this guidance due to various factors including, but not limited to, trade policy changes and trade restrictions, product demand, order cancellations and delays, competition, tariffs and retaliatory tariffs, currency fluctuations and general economic conditions. The current uncertainty related to the trade environment and tariff policies increases the risks to the outlook that we have provided. This guidance is based upon current market conditions and expectations and is subject to the risks outlined in the Company's reports filed with the SEC and assumes exchange rates relative to the U.S. dollar of euro 0.88, Japanese yen 157 and Chinese yuan 6.74, respectively.
Additional supplemental financial information is provided in the unaudited Financial Data Workbook and Third Quarter 2026 Earnings Call Presentation available on the investor relations section of the Company's website at investor.ipgphotonics.com .
The Company will hold a conference call today, November 3, 2026 at 10:00 am ET. To access the call, please dial 877-407-6184 in the US or 201-389-0877 internationally. A live webcast of the call will also be available and archived on the investor relations section of the Company's website at investor.ipgphotonics.com .
Innovation is at the heart of IPG Photonics. As a global leader in laser technology, we apply light to transform the world. From manufacturing to medical and beyond, our breakthrough laser solutions power our customers’ success and expand what's possible. Discover more at www.ipgphotonics.com. 2
Information and statements provided by IPG and its employees, including statements in this press release, that relate to future plans, events or performance are forward-looking statements. These statements involve risks and uncertainties. Any statements in this press release that are not statements of historical fact are forward-looking statements, including those statements related to strength of our technology, disciplined execution, and continued progress in expanding our presence in attractive, higher-growth markets, the expected timing of the closing of our acquisition of Lumibird Medical and the expectation that the acquisition will increase revenue in Advanced Solutions and strengthen our reach and accelerate growth across medical markets, strategic growth initiatives, driving adoption for our differentiated laser and photonics solutions that deliver measurable value to customers, driving profitable growth through innovation, technology differentiation, and operational excellence across our portfolio, revenue, adjusted gross margin and adjusted operating expenses outlook, adjusted earnings per diluted share and adjusted EBITDA guidance, including the expected impact of tariffs, and the impact of the U.S. dollar on our guidance for the fourth quarter of 2026. Factors that could cause actual results to differ materially include risks and uncertainties, including risks associated with the strength or weakness of business conditions in industries and geographic markets that IPG serves, particularly the effect of downturns in the markets IPG serves; uncertainties and adverse changes in the general economic conditions of markets; inability to manage risks associated with international customers and operations; changes in trade controls and tariff policies; IPG's ability to penetrate new applications for fiber lasers and increase market share; the rate of acceptance and penetration of IPG's products; foreign currency fluctuations; high levels of fixed costs from IPG's vertical integration; the appropriateness of IPG's manufacturing capacity for the level of demand; competitive factors, including declining average selling prices; the effect of acquisitions and investments; inventory write-downs; asset impairment charges; intellectual property infringement claims and litigation; interruption in supply of key components; manufacturing risks; government regulations and trade sanctions; and other risks identified in IPG's SEC filings. Readers are encouraged to refer to the risk factors described in IPG's Annual Report on Form 10-K (filed with the SEC for the fiscal year ended December 31, 2025), IPG's Quarterly Report on Form 10-Q (filed with the SEC for the quarter ended June 30, 2026), and other reports filed with the SEC, as applicable. Actual results, events and performance may differ materially. Readers are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date hereof. IPG undertakes no obligation to update the forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. 3
September 30, 2026 (In thousands, ASSETS except share December 31, Current assets: data) 2025 ────────────────────────────────────────────────────────────────────────────── Cash and cash $ 710,688 $ 403,790 equivalents Short-term 215,304 435,538 investments Accounts 191,150 181,734 receivable, net Inventories 337,890 313,416 Prepaid income 33,145 43,196 taxes Prepaid expenses and other 54,460 45,766 current assets Total current 1,542,637 1,423,440 assets Long-term — 76,533 investments Deferred income 122,235 123,889 taxes, net Goodwill 70,281 71,735 Intangible 42,777 49,933 assets, net Property, plant and equipment, 648,326 637,516 net Other assets 45,787 41,234 Total assets $ 2,472,043 $ 2,424,280 LIABILITIES AND EQUITY Current liabilities: Accounts payable $ 48,782 $ 39,288 Accrued expenses and other 204,874 184,849 current liabilities Income taxes 3,858 9,900 payable Total current 257,514 234,037 liabilities Other long-term liabilities and 59,581 62,113 deferred income taxes Total 317,095 296,150 liabilities Commitments and contingencies Stockholders' equity: Common stock, $0.0001 par value, 175,000,000 shares authorized; 57,380,668 and 42,508,140 shares issued and outstanding, respectively, at 6 6 September 30, 2026; 56,964,939 and 42,127,067 shares issued and outstanding, respectively, at December 31, 2025. Treasury stock, at cost, 14,872,528 and 14,837,872 shares held at -1,558,277 -1,555,629 September 30, 2026 and December 31, 2025, respectively. Additional 1,097,673 1,077,172 paid-in capital Retained 2,672,063 2,644,964 earnings Accumulated other -56,517 -38,383 comprehensive loss Total stockholders' 2,154,948 2,128,130 equity Total liabilities and $ 2,472,043 $ 2,424,280 stockholders' equity
Nine Months Ended September 30, Cash flows from 2026 operating activities: (In thousands) 2025 ────────────────────────────────────────────────────────────────────────────── Net income $ 27,099 $ 17,826 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and 47,377 46,799 amortization Impairment charges 17,805 — Provisions for inventory, warranty & 33,594 31,766 bad debt Other 25,081 21,119 Changes in assets and liabilities that provided (used) cash: Accounts receivable 1,535 18,787 and accounts payable Inventories -60,189 -52,005 Other -13,771 -37,757 Net cash provided by operating 78,531 46,535 activities Cash flows from investing activities: Purchases of and deposits on property, -54,437 -60,907 plant and equipment Proceeds from sales of property, plant 2,204 605 and equipment Purchases of -360,732 -866,402 investments Purchases of equity -8,000 — investment Proceeds from maturities of 663,124 633,731 investments Deposit received from buyer for assets 2,000 — held for sale Other 111 69 Net cash provided by (used in) investing 244,270 -292,904 activities Cash flows from financing activities: Payments for taxes related to net share settlement of equity awards less proceeds from issuance -11,053 -4,316 of common stock under employee stock option and purchase plans Purchase of treasury stock net of excise -2,648 -46,603 tax, at cost Net cash used in -13,701 -50,919 financing activities Effect of changes in exchange rates on cash, cash equivalents -1,727 23,274 and cash held for sale Net increase (decrease) in cash, cash 307,373 -274,014 equivalents and cash held for sale Cash and cash equivalents — 403,790 620,040 Beginning of period Cash, cash equivalents and cash held for $ 711,163 $ 346,026 sale — End of period Supplemental disclosures of cash flow information: Cash paid for interest $ 54 $ 136 Cash paid for income taxes, net of $ 9,273 $ 44,258 refunds
We refer to certain financial measures that are not recognized under United States generally accepted accounting principles (“GAAP”) and are provided as supplemental information to enhance understanding of the Company’s financial performance. Such non-GAAP financial measures should not be considered superior to, as a substitute for or alternative to, and should be considered in conjunction with, the GAAP financial measure presented by the Company. The following information provides the definition of adjusted gross profit, adjusted gross margin, adjusted operating expense and resultant adjusted operating income, EBITDA, adjusted EBITDA, adjusted net income, adjusted net earnings per share (EPS), and adjusted tax rate as presented, which are financial measures that are not calculated or presented in accordance with GAAP, and reconciliation to the most directly comparable financial measures calculated and presented in accordance with GAAP. The Company has provided adjusted gross profit, adjusted gross margin, adjusted operating expense and resultant adjusted operating income, EBITDA, adjusted EBITDA, adjusted net income, adjusted EPS, and an adjusted tax rate as supplemental information and in addition to the financial measures presented by the Company that are calculated and presented in accordance with GAAP. We define adjusted gross profit as reported gross profit, adjusted for non- recurring, infrequent, or unusual charges, including acquisition and integration charges and amortization of acquisition-related intangibles. We define adjusted gross margin as adjusted gross profit divided by total revenue. We define adjusted operating expense and resultant adjusted operating income as reported operating expenses and resultant operating income, adjusted for non- recurring, infrequent, or unusual charges, including impairment charges, settlement and fees of litigation matters, restructuring charges, acquisition and integration charges, amortization of acquisition-related intangibles, foreign exchange gains/losses and gain/loss on disposal of assets/divestiture. We define EBITDA as net income plus interest expense (income), provision for income taxes, depreciation expense, and amortization expense. We define adjusted EBITDA as EBITDA adjusted for non-recurring, infrequent, or unusual charges, and other adjustments that the Company believes appropriate, including stock-based compensation, restructuring charges, impairment charges, settlement and fees of litigation matters, acquisition and integration charges, foreign exchange gains/losses and gain/loss on disposal of assets/divestiture.
We define adjusted net income as reported net income, adjusted for non- recurring, infrequent, or unusual charges, and other adjustments that the Company believes appropriate, including impairment charges, settlement and fees of litigation matters, restructuring charges, amortization of acquisition- related intangibles, acquisition and integration charges, foreign exchange gains/losses and gain/loss on disposal of assets/divestiture, certain discrete tax items and non-GAAP income tax reconciling adjustments. We define adjusted EPS as adjusted net income divided by the weighted-average diluted shares outstanding.
We define adjusted tax rate as the GAAP tax rate, adjusted for discrete tax items and the net impact of non-GAAP adjustments.
Management believes that these non-GAAP financial measures provide additional means of evaluating period-over-period operating performance. Specifically, these non-GAAP financial measures provide management with additional means to understand and evaluate the operating results and trends in our ongoing business by eliminating certain non-cash expenses and other items that management believes might otherwise make comparisons of our ongoing business with prior periods more difficult, obscure trends in ongoing operations, or reduce management’s ability to make useful forecasts.
In addition, management understands that some investors and financial analysts find this information helpful in analyzing our financial and operational performance and comparing this performance to our peers and competitors. However, these non-GAAP financial measures have limitations as an analytical tool and are not intended to be an alternative to financial measures prepared in accordance with GAAP. In addition, it should be noted that these non-GAAP financial measures may be different from non-GAAP measures used by other companies. Management may, however, utilize other measures to illustrate performance in the future. Investors are encouraged to review the reconciliation of these non-GAAP measures to their most directly comparable GAAP financial measures. A reconciliation of our non-GAAP financial measures to their most directly comparable GAAP measures has been provided below. These non-GAAP measures exclude (i) amortization of acquisition-related intangibles, (ii) restructuring charges, (iii) acquisition and integration costs, (iv) impairment charges, (v) foreign 7
exchange gains/losses, (vi) interest income, (vii) benefit (provision) from income taxes, (viii) depreciation, (ix) amortization, (x) stock-based compensation, (xi) gain/loss on disposal of assets/divestiture, (xii) settlement and fees of litigation matters, (xiii) certain discrete tax items, and (xiv) non-GAAP income tax reconciling adjustments.
We have not provided a quantitative reconciliation of forward-looking Non-GAAP adjusted earnings per diluted share and adjusted EBITDA to their most directly comparable GAAP financial measures because we are unable to estimate with reasonable certainty the ultimate timing or amount of certain significant items without unreasonable efforts. This is due to the inherent difficulty of forecasting the timing and/or amount of various items that would impact adjusted earnings per diluted share and adjusted EBITDA. This includes items that have not yet occurred, are out of the Company’s control, cannot be reasonably predicted and/or for which there would not be any meaningful adjustment or difference. For the same reasons, the Company is unable to address the probable significance of the unavailable information. Our non-GAAP tax provision for the fiscal third quarter of 2026 is 23%. The difference between our GAAP income tax provision and our non-GAAP income tax provision is presented as non-GAAP income tax reconciling adjustments. 8
Reconciliation of GAAP to Non-GAAP Net Income, and GAAP to Non-GAAP Net Income per Share, Diluted
Full text with the tables
Exhibit 99.1
IPG PHOTONICS ANNOUNCES THIRD QUARTER 2026 FINANCIAL RESULTS
Double-Digit Revenue Growth Driven by Strategic Initiatives Across Industrial
and Advanced Solutions
Focused on Driving Margin Expansion
MARLBOROUGH, Mass. –
November 3, 2026 - IPG Photonics Corporation (NASDAQ: IPGP) today reported
financial results for the third quarter ended September 30, 2026.
…
…
…
… T… N…
… M… M…
… E… E…
… S… S…
… 2… 3… 2… C… … 3… … …
──────────────────────────────────────────────────────────────────────────────
… $ 2… $ 2… … % $ 8… $ 7… 14 %
… 4… % 3… % 3… % 3… %
…
… $ 2… $ 7… NM $ 1… $ 9… …
…
… 7… % 3… % 2… % 1… %
…
… $ 2… $ 7… … % $ 2… $ 1… 52 %
…
…
… $ 0… $ 0… … % $ 0… $ 0… 50 %
…
…
…
…
…
… 4… % 3… % 3… % 3… %
…
… $ 5… $ 3… … % $ 1… $ 1… 34 %
…
…
…
… $ 0… $ 0… … % $ 1… $ 0… 55 %
…
…
*Adjusted gross margin, adjusted EBITDA and adjusted earnings per diluted share
include non-GAAP adjustments. A reconciliation from GAAP to non-GAAP metrics is
provided in this earnings release.
NM - not meaningful .
Management Comments
“We delivered our fourth consecutive quarter of double-digit year-over-year
revenue growth, with revenue above the midpoint of our guidance,” said Dr. Mark
Gitin, Chief Executive Officer of IPG Photonics. “Our performance reflects the
strength of our technology, disciplined execution, and continued progress in
expanding our presence in attractive, higher-growth markets. Strong demand for
our differentiated welding and additive manufacturing solutions drove growth in
Industrial Solutions while disciplined execution of our key strategic
initiatives across defense and semiconductor markets led to strong growth in
Advanced Solutions. Additionally, I anticipate that our acquisition of Lumibird
Medical, which is expected to close in the fourth quarter, will further
strengthen our reach, accelerate growth across medical markets, and increase
revenue in Advanced Solutions.”
Financial Highlights
T… N…
M… M…
E… E…
… S… S…
… 3… 3…
… 2… … C… 2… … C…
──────────────────────────────────────────────────────────────────────────────
… $ 2… $ 2… … % $ … $ 6… … %
…
… 4… … … % 1… … 5 %
…
… $ 2… $ 2… … % $ … $ 7… … %
1
Exhibit 99.1
Third quarter revenue of $288 million increased 15% year over year, driven by
12% growth in Industrial Solutions and 33% growth in Advanced Solutions. Changes
in foreign exchange rates increased revenue by approximately 1%. Industrial
Solutions sales, accounting for 83% of total revenue, were driven by strong
performance in welding and additive manufacturing applications. Advanced
Solutions sales improved, driven by higher sales in semico nductor and defense
applications. Emerging growth products accounted for 52% of total revenue, down
from 58% in the prior quarter due to product mix. By region, sales increased 14%
in Asia and 33% in North America and decreased 1% in Europe on a year-over-year
basis.
GAAP gross margin of 40.7% and adjusted gross margin of 41.0% increased year
over year, driven by lower product costs and $5.0 million in net tariff refunds
recorded in the period, partially offset by lower fixed cost absorption. Net
income was $20 million, or $0.47 per diluted share, and a djusted EBITDA was $52
million and adjusted earnings per diluted share (EPS) was $0.61 in the third
quarter. During the third quarter, IPG generated $46 million in cash flow from
operations and spent $17 million on capital expenditures.
Business Outlook and Financial Guidance
“Our third quarter book-to-bill was approximately one as we continued to see
improved industrial demand and executed on our strategic growth initiatives,
driving adoption for our differentiated laser and photonics solutions that
deliver measurable value to customers. As we move forward, we remain focused on
driving profitable growth through innovation, technology differentiation, and
operational excellence across our portfolio, ” concluded Dr. Gitin.
For the fourth quarter of 2026, IPG expects revenue of $265 million to $295
million, adjusted gross margin between 37.0% and 40.0% and adjusted operating
expenses of $91 million to $94 million. IPG anticipates delivering adjusted
earnings per diluted share in the range of $0.30 to $0.60 and adjusted EBITDA in
the range of $33 million to $50 million. The guidance assumes no contribution
from the acquisition of Lumibird Medical.
As discussed in more detail in the "Safe Harbor" passage of this news release,
actual results may differ from this guidance due to various factors including,
but not limited to, trade policy changes and trade restrictions, product demand,
order cancellations and delays, competition, tariffs and retaliatory tariffs,
currency fluctuations and general economic conditions. The current uncertainty
related to the trade environment and tariff policies increases the risks to the
outlook that we have provided. This guidance is based upon current market
conditions and expectations and is subject to the risks outlined in the
Company's reports filed with the SEC and assumes exchange rates relative to the
U.S. dollar of euro 0.88, Japanese yen 157 and Chinese yuan 6.74, respectively.
Supplemental Financial Information
Additional supplemental financial information is provided in the unaudited
Financial Data Workbook and Third Quarter 2026 Earnings Call Presentation
available on the investor relations section of the Company's website at
investor.ipgphotonics.com .
Conference Call Reminder
The Company will hold a conference call today, November 3, 2026 at 10:00 am ET.
To access the call, please dial 877-407-6184 in the US or 201-389-0877
internationally. A live webcast of the call will also be available and archived
on the investor relations section of the Company's website at
investor.ipgphotonics.com .
Contact
Eugene Fedotoff
Senior Director, Investor Relations
IPG Photonics Corporation
508-597-4713
[email protected]
About IPG Photonics Corporation
Innovation is at the heart of IPG Photonics. As a global leader in laser
technology, we apply light to transform the world. From manufacturing to medical
and beyond, our breakthrough laser solutions power our customers’ success and
expand what's possible. Discover more at www.ipgphotonics.com.
2
Exhibit 99.1
Safe Harbor Statement
Information and statements provided by IPG and its employees, including
statements in this press release, that relate to future plans, events or
performance are forward-looking statements. These statements involve risks and
uncertainties. Any statements in this press release that are not statements of
historical fact are forward-looking statements, including those statements
related to strength of our technology, disciplined execution, and continued
progress in expanding our presence in attractive, higher-growth markets, the
expected timing of the closing of our acquisition of Lumibird Medical and the
expectation that the acquisition will increase revenue in Advanced Solutions and
strengthen our reach and accelerate growth across medical markets, strategic
growth initiatives, driving adoption for our differentiated laser and photonics
solutions that deliver measurable value to customers, driving profitable growth
through innovation, technology differentiation, and operational excellence
across our portfolio, revenue, adjusted gross margin and adjusted operating
expenses outlook, adjusted earnings per diluted share and adjusted EBITDA
guidance, including the expected impact of tariffs, and the impact of the U.S.
dollar on our guidance for the fourth quarter of 2026. Factors that could cause
actual results to differ materially include risks and uncertainties, including
risks associated with the strength or weakness of business conditions in
industries and geographic markets that IPG serves, particularly the effect of
downturns in the markets IPG serves; uncertainties and adverse changes in the
general economic conditions of markets; inability to manage risks associated
with international customers and operations; changes in trade controls and
tariff policies; IPG's ability to penetrate new applications for fiber lasers
and increase market share; the rate of acceptance and penetration of IPG's
products; foreign currency fluctuations; high levels of fixed costs from IPG's
vertical integration; the appropriateness of IPG's manufacturing capacity for
the level of demand; competitive factors, including declining average selling
prices; the effect of acquisitions and investments; inventory write-downs; asset
impairment charges; intellectual property infringement claims and litigation;
interruption in supply of key components; manufacturing risks; government
regulations and trade sanctions; and other risks identified in IPG's SEC
filings. Readers are encouraged to refer to the risk factors described in IPG's
Annual Report on Form 10-K (filed with the SEC for the fiscal year ended
December 31, 2025), IPG's Quarterly Report on Form 10-Q (filed with the SEC for
the quarter ended June 30, 2026), and other reports filed with the SEC, as
applicable. Actual results, events and performance may differ materially.
Readers are cautioned not to place undue reliance on the forward-looking
statements, which speak only as of the date hereof. IPG undertakes no obligation
to update the forward-looking statements to reflect events or circumstances
after the date hereof or to reflect the occurrence of unanticipated events,
except as required by law.
3
Exhibit 99.1
IPG PHOTONICS CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(UNAUDITED)
Three
Months
Ended
Septem…
30,
2026
(In Nine
thousa… Months
except Ended
per Septe…
share 30,
data) 2025 2026 2025
──────────────────────────────────────────────────────────────────────────────
Net $ 287,5… $ 250,792 $ 831,577 $ 729,3…
sales
Cost
of 170,4… 151,787 502,500 446,9…
sales
Gross 117,0… 99,005 329,077 282,3…
prof…
Oper…
expe…
Sales
and 23,934 23,771 72,286 73,753
mark…
Rese…
and 31,335 30,358 95,648 88,631
deve…
Gene…
and 37,502 35,092 110,139 102,7…
admi…
Sett…
of — — 13,334 —
liti…
matt…
Impa… 231 — 17,805 —
char…
Rest… — 425 — 425
char…
Loss
on 3,275 1,504 2,293 7,013
fore…
exch…
Total
oper… 96,277 91,150 311,505 272,6…
expe…
Oper… 20,777 7,855 17,572 9,786
inco…
Other
inco…
net:
Inte…
inco… 7,688 7,283 21,720 22,728
net
Other
(exp… -50 516 2,683 2,026
inco…
net
Total
other 7,638 7,799 24,403 24,754
inco…
Inco…
befo…
prov… 28,415 15,654 41,975 34,540
for
inco…
taxes
Prov…
for 8,142 8,191 14,876 16,714
inco…
taxes
Net $ 20,273 $ 7,463 $ 27,099 $ 17,826
inco…
Net
inco…
per
comm…
shar…
Basic $ 0.48 $ 0.18 $ 0.64 $ 0.42
Dilu… $ 0.47 $ 0.18 $ 0.63 $ 0.42
Weig…
aver…
comm…
shar…
outs…
Basic 42,531 42,199 42,416 42,427
Dilu… 42,840 42,556 42,904 42,659
4
Exhibit 99.1
IPG PHOTONICS CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(UNAUDITED)
September 30,
2026
(In thousands,
ASSETS except share December 31,
Current assets: data) 2025
──────────────────────────────────────────────────────────────────────────────
Cash and cash $ 710,688 $ 403,790
equivalents
Short-term 215,304 435,538
investments
Accounts 191,150 181,734
receivable, net
Inventories 337,890 313,416
Prepaid income 33,145 43,196
taxes
Prepaid expenses
and other 54,460 45,766
current
assets
Total current 1,542,637 1,423,440
assets
Long-term — 76,533
investments
Deferred income 122,235 123,889
taxes, net
Goodwill 70,281 71,735
Intangible 42,777 49,933
assets, net
Property, plant
and equipment, 648,326 637,516
net
Other assets 45,787 41,234
Total assets $ 2,472,043 $ 2,424,280
LIABILITIES AND
EQUITY
Current
liabilities:
Accounts payable $ 48,782 $ 39,288
Accrued expenses
and other 204,874 184,849
current
liabilities
Income taxes 3,858 9,900
payable
Total current 257,514 234,037
liabilities
Other long-term
liabilities and 59,581 62,113
deferred
income taxes
Total 317,095 296,150
liabilities
Commitments and
contingencies
Stockholders'
equity:
Common stock,
$0.0001 par
value,
175,000,000
shares
authorized;
57,380,668 and
42,508,140
shares issued
and outstanding,
respectively, at 6 6
September 30,
2026; 56,964,939
and
42,127,067
shares issued
and
outstanding,
respectively, at
December
31, 2025.
Treasury stock,
at cost,
14,872,528 and
14,837,872
shares held at -1,558,277 -1,555,629
September 30,
2026 and
December 31,
2025,
respectively.
Additional 1,097,673 1,077,172
paid-in capital
Retained 2,672,063 2,644,964
earnings
Accumulated
other -56,517 -38,383
comprehensive
loss
Total
stockholders' 2,154,948 2,128,130
equity
Total
liabilities and $ 2,472,043 $ 2,424,280
stockholders'
equity
5
Exhibit 99.1
IPG PHOTONICS CORPORATION
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
Nine Months Ended
September 30,
Cash flows from 2026
operating activities: (In thousands) 2025
──────────────────────────────────────────────────────────────────────────────
Net income $ 27,099 $ 17,826
Adjustments to
reconcile net income
to
net cash provided by
operating
activities:
Depreciation and 47,377 46,799
amortization
Impairment charges 17,805 —
Provisions for
inventory, warranty & 33,594 31,766
bad
debt
Other 25,081 21,119
Changes in assets and
liabilities that
provided (used) cash:
Accounts receivable 1,535 18,787
and accounts payable
Inventories -60,189 -52,005
Other -13,771 -37,757
Net cash provided by
operating 78,531 46,535
activities
Cash flows from
investing activities:
Purchases of and
deposits on property, -54,437 -60,907
plant and equipment
Proceeds from sales of
property, plant 2,204 605
and equipment
Purchases of -360,732 -866,402
investments
Purchases of equity -8,000 —
investment
Proceeds from
maturities of 663,124 633,731
investments
Deposit received from
buyer for assets 2,000 —
held for sale
Other 111 69
Net cash provided by
(used in) investing 244,270 -292,904
activities
Cash flows from
financing activities:
Payments for taxes
related to net share
settlement of equity
awards less
proceeds from issuance -11,053 -4,316
of common stock
under employee stock
option and purchase
plans
Purchase of treasury
stock net of excise -2,648 -46,603
tax, at cost
Net cash used in -13,701 -50,919
financing activities
Effect of changes in
exchange rates on
cash, cash equivalents -1,727 23,274
and cash held for
sale
Net increase
(decrease) in cash,
cash 307,373 -274,014
equivalents and cash
held for sale
Cash and cash
equivalents — 403,790 620,040
Beginning of
period
Cash, cash equivalents
and cash held for $ 711,163 $ 346,026
sale — End of period
Supplemental
disclosures of cash
flow
information:
Cash paid for interest $ 54 $ 136
Cash paid for income
taxes, net of $ 9,273 $ 44,258
refunds
6
Exhibit 99.1
IPG PHOTONICS CORPORATION
SUPPLEMENTAL SCHEDULE OF NON-GAAP FINANCIAL MEASURES (UNAUDITED)
Use of Non-GAAP Adjusted Financial Information
We refer to certain financial measures that are not recognized under United
States generally accepted accounting principles (“GAAP”) and are provided as
supplemental information to enhance understanding of the Company’s financial
performance. Such non-GAAP financial measures should not be considered superior
to, as a substitute for or alternative to, and should be considered in
conjunction with, the GAAP financial measure presented by the Company. The
following information provides the definition of adjusted gross profit, adjusted
gross margin, adjusted operating expense and resultant adjusted operating
income, EBITDA, adjusted EBITDA, adjusted net income, adjusted net earnings per
share (EPS), and adjusted tax rate as presented, which are financial measures
that are not calculated or presented in accordance with GAAP, and reconciliation
to the most directly comparable financial measures calculated and presented in
accordance with GAAP. The Company has provided adjusted gross profit, adjusted
gross margin, adjusted operating expense and resultant adjusted operating
income, EBITDA, adjusted EBITDA, adjusted net income, adjusted EPS, and an
adjusted tax rate as supplemental information and in addition to the financial
measures presented by the Company that are calculated and presented in
accordance with GAAP.
We define adjusted gross profit as reported gross profit, adjusted for non-
recurring, infrequent, or unusual charges, including acquisition and integration
charges and amortization of acquisition-related intangibles.
We define adjusted gross margin as adjusted gross profit divided by total
revenue.
We define adjusted operating expense and resultant adjusted operating income as
reported operating expenses and resultant operating income, adjusted for non-
recurring, infrequent, or unusual charges, including impairment charges,
settlement and fees of litigation matters, restructuring charges, acquisition
and integration charges, amortization of acquisition-related intangibles,
foreign exchange gains/losses and gain/loss on disposal of assets/divestiture.
We define EBITDA as net income plus interest expense (income), provision for
income taxes, depreciation expense, and amortization expense.
We define adjusted EBITDA as EBITDA adjusted for non-recurring, infrequent, or
unusual charges, and other adjustments that the Company believes appropriate,
including stock-based compensation, restructuring charges, impairment charges,
settlement and fees of litigation matters, acquisition and integration charges,
foreign exchange gains/losses and gain/loss on disposal of assets/divestiture.
We define adjusted net income as reported net income, adjusted for non-
recurring, infrequent, or unusual charges, and other adjustments that the
Company believes appropriate, including impairment charges, settlement and fees
of litigation matters, restructuring charges, amortization of acquisition-
related intangibles, acquisition and integration charges, foreign exchange
gains/losses and gain/loss on disposal of assets/divestiture, certain discrete
tax items and non-GAAP income tax reconciling adjustments.
We define adjusted EPS as adjusted net income divided by the weighted-average
diluted shares outstanding.
We define adjusted tax rate as the GAAP tax rate, adjusted for discrete tax
items and the net impact of non-GAAP adjustments.
Management believes that these non-GAAP financial measures provide additional
means of evaluating period-over-period operating performance. Specifically,
these non-GAAP financial measures provide management with additional means to
understand and evaluate the operating results and trends in our ongoing business
by eliminating certain non-cash expenses and other items that management
believes might otherwise make comparisons of our ongoing business with prior
periods more difficult, obscure trends in ongoing operations, or reduce
management’s ability to make useful forecasts.
In addition, management understands that some investors and financial analysts
find this information helpful in analyzing our financial and operational
performance and comparing this performance to our peers and competitors.
However, these non-GAAP financial measures have limitations as an analytical
tool and are not intended to be an alternative to financial measures prepared in
accordance with GAAP. In addition, it should be noted that these non-GAAP
financial measures may be different from non-GAAP measures used by other
companies. Management may, however, utilize other measures to illustrate
performance in the future. Investors are encouraged to review the reconciliation
of these non-GAAP measures to their most directly comparable GAAP financial
measures. A reconciliation of our non-GAAP financial measures to their most
directly comparable GAAP measures has been provided below. These non-GAAP
measures exclude (i) amortization of acquisition-related intangibles, (ii)
restructuring charges, (iii) acquisition and integration costs, (iv) impairment
charges, (v) foreign
7
Exhibit 99.1
exchange gains/losses, (vi) interest income, (vii) benefit (provision) from
income taxes, (viii) depreciation, (ix) amortization, (x) stock-based
compensation, (xi) gain/loss on disposal of assets/divestiture, (xii) settlement
and fees of litigation matters, (xiii) certain discrete tax items, and (xiv)
non-GAAP income tax reconciling adjustments.
We have not provided a quantitative reconciliation of forward-looking Non-GAAP
adjusted earnings per diluted share and adjusted EBITDA to their most directly
comparable GAAP financial measures because we are unable to estimate with
reasonable certainty the ultimate timing or amount of certain significant items
without unreasonable efforts. This is due to the inherent difficulty of
forecasting the timing and/or amount of various items that would impact adjusted
earnings per diluted share and adjusted EBITDA. This includes items that have
not yet occurred, are out of the Company’s control, cannot be reasonably
predicted and/or for which there would not be any meaningful adjustment or
difference. For the same reasons, the Company is unable to address the probable
significance of the unavailable information.
Our non-GAAP tax provision for the fiscal third quarter of 2026 is 23%. The
difference between our GAAP income tax provision and our non-GAAP income tax
provision is presented as non-GAAP income tax reconciling adjustments.
8
Exhibit 99.1
IPG PHOTONICS CORPORATION
SUPPLEMENTAL SCHEDULE OF NON-GAAP MEASURES (UNAUDITED)
Reconciliation of Gross Profit to Adjusted Gross Profit, Adjusted Gross Margin
Three
Mont…
Ended
Sept…
30, Nine
2026 Mont…
(in Ended
thou… Sept…
exce… 30,
perc… 2025 2026 2025
──────────────────────────────────────────────────────────────────────────────
Gro… $ 117,… $ 99,005 $ 329,0… $ 282,…
pro…
Gro… 40.7% 39.5% 39.6% 38.7%
mar…
Amo…
of 720 851 2,360 2,928
acq…
int…
Acq…
and — — — 482
int…
cha…
Adj…
gro… $ 117,… $ 99,856 $ 331,4… $ 285,…
pro…
Adj…
gro… 41.0% 39.8% 39.9% 39.2%
mar…
Reconciliation of Operating Expenses to Adjusted Operating Expenses
Thr…
Mon…
End… Nine
Sep… Mon…
30, End…
2026 Sep…
(in 30,
tho… 20… 2026 20…
──────────────────────────────────────────────────────────────────────────────
O… $ 96,… $ 91… $ 311… $ 27…
e…
L…
A…
of 1,2… 1,… 3,7… 4,…
a…
i…
A…
a… 151 246 987 1,…
i…
c…
I… 231 — 17,… —
c…
R… 149 425 500 425
c…
S…
a…
f… — — 14,… —
of
l…
m…
L…
on 3,2… 1,… 2,2… 7,…
f…
e…
A…
o… $ 91… $ 87,… $ 27… $ 258…
e…
Reconciliation of Operating Income to Adjusted Operating Income
Thr…
Mon…
End… Nine
Sep… Mon…
30, End…
2026 Sep…
(in 30,
tho… 20… 2026 20…
──────────────────────────────────────────────────────────────────────────────
O… $ 20,… $ 7,… $ 17,… $ 9,…
i…
A…
of 1,9… 2,… 6,0… 7,…
a…
i…
A…
a… 151 246 987 2,…
i…
c…
I… 231 — 17,… —
c…
R… 149 425 500 425
c…
S…
a…
f… — — 14,… —
of
l…
m…
L…
on 3,2… 1,… 2,2… 7,…
f…
e…
A…
o… $ 26… $ 12,… $ 59… $ 27,…
i…
9
Exhibit 99.1
Reconciliation of Net income to Adjusted EBITDA
Three
Mont…
Ended Nine
Sept… Mont…
30, Ended
2026 Sept…
(in 30,
thou… 2025 2026 2025
──────────────────────────────────────────────────────────────────────────────
Net $ 20,2… $ 7,463 $ 27,099 $ 17,8…
inc…
Int…
inc… -7,6… -7,283 -21,7… -22,…
net
Pro…
for 8,142 8,191 14,876 16,7…
inc…
tax…
Dep… 12,9… 12,392 38,447 36,1…
Amo… 2,976 3,240 8,930 10,6…
EBI… $ 36,6… $ 24,003 $ 67,632 $ 58,6…
Imp… 231 — 17,805 —
cha…
Sto…
bas… 11,0… 10,780 31,597 32,8…
com…
Res… 149 425 500 425
cha…
Acq…
and 151 246 987 2,305
int…
cha…
Set…
and
fees — — 14,435 —
of
lit…
mat…
Loss
on 3,275 1,504 2,293 7,013
for…
exc…
Adj… $ 51,5… $ 36,958 $ 135,2… $ 101,…
EBI…
Reconciliation of GAAP to Non-GAAP Net Income, and GAAP to Non-GAAP Net Income
per Share, Diluted
Three
Months
Ended
Septem…
30,
2026
(in Nine
thousa… Months
except Ended
per Septem…
share 30,
data) 2025 2026 2025
──────────────────────────────────────────────────────────────────────────────
Net $ 20,273 $ 7,463 $ 27,099 $ 17,826
income
Impai… 231 — 17,805 —
charg…
Amort…
of 1,951 2,402 6,061 7,498
acqui…
intan…
Restr… 149 425 500 425
charg…
Acqui…
and 151 246 987 2,305
integ…
charg…
Settl…
and
fees — — 14,435 —
of
litig…
matte…
Loss
on 3,275 1,504 2,293 7,013
forei…
excha…
Certa…
discr… 949 3,414 84 8,303
tax
items
Tax
impact
of -711 -613 -5,337 -2,471
non-G…
adjus…
Adjus…
net $ 26,268 $ 14,841 $ 63,927 $ 40,899
income
Adjus…
net
earni… $ 0.61 $ 0.35 $ 1.49 $ 0.96
per
dilut…
share
Weigh…
avera…
dilut… 42,840 42,556 42,904 42,659
shares
outst…
Reconciliation of GAAP to Non-GAAP Effective Tax Rate
Three Nine
Months Months
Ended Ended
Septem… Septemb…
30, 30,
2026 2025 2026 2025
Tax 29 % 52 % 35 % 48 %
rate
Discr…
tax -3 % -22 % — % -24 %
items
Net
impact
of -3 % -3 % -11 % -3 %
non-G…
adjus…
Adjus…
tax 23 % 27 % 24 % 21 %
rate
10